VI (GPVI) is a type I transmembrane protein of 58-60 kDa that belongs to the immunoglobulin superfamily and whose expression is restricted to the megakaryocyte lineage.
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with the homodimeric γ chain common to Fc receptors (FcRγ), whose cytoplasmic domains each bears a signaling motif known as immunoreceptor tyrosine-based activation motif (ITAM). 15, 16 Upon ligand binding, the Src family kinases Lyn and Fyn mediate phosphorylation of the ITAM tyrosine residues that transmit activation signals. 17 Although GPVI in its dimeric form binds collagen with a relatively high affinity, 10, 18 it is considered as a signaling rather than an adhesion receptor, as its interaction with collagen is a prerequisite for the activation of platelet integrins, including that of the collagen receptor integrin α2β1. [6] [7] [8] 19, 20 GPVI-dependent signaling indeed ensures firm adhesion and aggregation through activation of platelets. In addition, it has been shown that GPVI interaction with immobilized collagen related peptide (CRP), a synthetic peptide that mimics the triple-helical structure of collagen and specifically engages GPVI, 21, 22 is transient and not sufficient for firm platelet adhesion under flow, thus arguing against a role for GPVI in triggering platelet adhesion to collagen. 20, 23 Instead, it has been proposed that the interaction between
GPIbα and collagen-bound von Willebrand factor (VWF) would play a prominent role in initiating platelet adhesion to collagen, especially at higher shear, with GPVI-dependent signaling taking over integrin activation subsequently. 20, 23 Nonetheless, it should be noted that several studies have shown that GPVI permits platelet adhesion to fibrillar collagen irrespective of integrin activation in both static and flow conditions. 6, 7, [23] [24] [25] Moreover, absence or inhibition of GPVI was shown to cause a drastic reduction in platelet adhesion to fibrillar collagen, despite normal levels of GPIbα. 6, 7, 26, 27 Therefore, although
GPIbα primes adhesion to collagen and integrin activation reinforces it and allows aggregation, there is evidence that GPVI can support platelet adhesion to fibrillar collagen. In recent years, laminins, 28, 29 fibrin, 30, 31 and fibronectin 32, 33 have also been identified as adhesive and/or activating ligands for GPVI. The fact that GPVI has multiple ligands suggests that GPVI interactions with the injured or diseased vessel wall could be more complex than what can be deduced from its interactions with CRP or purified collagen alone.
Considering the central role of GPVI in mediating collageninduced platelet activation, as well as its ability to potentiate other platelet activation pathways, [34] [35] [36] one could expect from GPVI to be a major player in primary hemostasis. However, although their platelets are highly refractory to collagen-induced activation, patients with genetic or acquired GPVI deficiency only have a mild bleeding disorder. 2, 3, [37] [38] [39] [40] [41] Those patients present a bleeding phenotype comparable to that of patients with moderate thrombocytopenia, which includes easy bruising, a prolonged bleeding time, and so-called spontaneous bleeding events like petechiae and epistaxis. Autoantibodies to GPVI can be associated with idiopathic thrombocytopenic purpura, 2, 37 which can be considered as a confounding factor in the setting of abnormal bleeding. Hence, it is worth noting that the bleeding phenotype of the first patient described with anti-GPVI antibodies persisted despite correction of thrombocytopenia by steroid therapy. 2 This indicated that the patient's bleeding tendency was a consequence of platelet dysfunction rather than of reduced platelet counts. Consistent with observations made in GPVI-deficient patients, inhibition, immunodepletion, or genetic deletion of GPVI in animals only had minor consequences on primary hemostasis. 42, 43 In contrast to its limited impact on primary hemostasis, GPVI deficiency conferred remarkable protection against thrombosis in a variety of in vitro and in vivo experimental models, including flow chamber-based assays using human atherosclerotic plaque material. 27, 33, [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] For these reasons, and despite some controversies, GPVI has been proposed as a promising target for antithrombotic therapy with reduced bleeding risk as compared to current antiplatelet therapies based on administration of aspirin and/or P2Y12 inhibitors. 42, 43 The mild bleeding manifestations in patients with GPVI deficiency suggest that either GPVI plays a modest role in hemostasis or, more likely, that its absence is overcome by compensatory and/ or redundant mechanisms. Among the many pathways of platelet activation, the protease-activated receptors (PARs) for thrombin and the relatively newly discovered hem-ITAM-containing platelet activation receptor for podoplanin, C-type lectin-like receptor 2 (CLEC-2), have both shown functional redundancy with GPVI in mouse models of hemostasis and thrombosis. 59, 60 It has also been shown that the requirement for GPVI-dependent signaling through Syk in platelet spreading on various matrix proteins can be bypassed by thrombin. 35 Taken together, these data suggest that 65, 66 ) have been described in the vicinity of blood vessels and could therefore engage platelet CLEC-2 through vascular breaches.
Around 10 years back, inflammation was identified as a cause of nontraumatic bleeding in thrombocytopenia. 67 The fact that inflammation can cause bleeding in thrombocytopenia has hinted that spontaneous bleeding in patients with thrombocytopenia or platelet dysfunction may not always be "spontaneous" but rather evoked by unsuspected underlying inflammatory reactions. In addition, it has revealed a so far unnoticed and uncharacterized protective function of platelets in inflammation where they continuously prevent bleeding from inflamed vessels. Experiments in mouse models of inflammation have indicated that, surprisingly, the hemostatic function of platelets in inflammation can operate independently of platelet aggregation, the main and best known mechanism of action of platelets in hemostasis. 68 As presented in further detail below, there is experimental evidence to suggest that there are situations where GPVI could play a predominant role in preventing inflammatory bleeding, notably in the skin. In the light of these findings, it is worth noting that inflammation-induced bleeding in humans and mice can take the form of cutaneous petechiae, 67 ,69,70 a manifestation shared by both thrombocytopenic and GPVI-deficient patients.
| PLATELETS AND GPVI IN INFLAMMATION
Platelets have long been considered primarily through the lens of hemostatic platelet plug formation and thrombosis, who both rely on integrin-mediated platelet aggregation. These proinflammatory effects of platelets involved the release of TA B L E 1 GPVI functions in inflammation. A non-exhaustive list of the various effects of GPVI deficiency or blockade in models of inflammation. anti-GBM: anti-glomerular basement membrane antibody; K/BxN serum: serum from K/BxN a mouse strain known to develop severe autoimmune inflammatory arthritis
Inflammation model Effect of GPVI deficiency or blockade References
Acute dermatitis (IgG immune-complex mediated)
• skin bleeding at the reaction site • reduced platelet recruitment to the inflamed skin • reduced reaction-induced serotonin secretion [94, 102] Peritonitis (IgG immune-complex mediated)
• decreased MMP-9 release in the peritoneal cavity • no bleeding [94] Rheumatoid arthritis (K/BxN serum)
• decreased vascular permeability in the inflamed joint • decreased production of proinflammatory platelet microparticles [80, 84] Glomerulonephritis (anti-GBM antibody)
• reduced platelet recruitment to the inflamed glomerulus [99] Myocardial Ischemia-Reperfusion (30 min long ligation of the left coronary artery)
• reduced neutrophil recruitment • reduced expression of inflammatory cytokines in the myocardium • reduced microthrombosis • improved microperfusion • reduced infarct size • intramyocardial bleeding [103] [104] [105] Cerebral Ischemia-Reperfusion (60 min long occlusion of middle cerebral artery)
• reduced infarct size • reduced thrombosis in ischemic cortices • improved microperfusion • no bleeding [113, 116, 136] Lung infection (Klebsiella pneumoniae)
• increased bacterial growth in infected lungs • increased MMP-9 release in the bronchoalveolar space • increased inflammatory cytokines in the bronchoalveolar space • reduced platelet recruitment and activation in the lung • reduced platelet-leukocyte complex formation in the lung • minor bleeding [148, 149] Acute lung injury (LPS inhalation)
• lung bleeding [102] Atherosclerosis (ApoE -/-mice)
• reduced platelet adhesion to atherosclerotic endothelium • reduced atherosclerotic lesion formation [26, 33] serotonin and microparticles in synovial fluid. Platelet serotonin and microparticles, respectively, induced endothelial gap formation in the synovial vasculature and the secretion of the neutrophil chemoattractant interleukin-8 by synovial fibroblasts, thus amplifying arthritis. The contribution of various platelet activation pathways to the inflammatory functions of platelets in this model was investigated using genetically deficient mice and pharmacologic blockade.
The G protein-coupled receptors for thromboxane A2 (TP) and ADP (P2Y12), GPIbα, and integrin αIIbβ3 were all found to be dispensable for microparticles generation and development of joint inflammation, which instead relied on GPVI. 84 The clinical observations of increased circulating platelet-derived factors (e.g, serotonin, platelet factor 4, β- 
107-109
An alternative explanation is that, having released their granules, platelets might become difficult to identify in transmission electron microscopy. [107] [108] [109] Renal intravital microscopy in a mouse model of IC-mediated glomerulonephritis has brought some insights on the interactions between platelets and the inflamed glomerulus vasculature. 99 Platelet recruitment to the glomerulus started within minutes of inflammation initiation and increased progressively during the course of the reaction. Primary adhesion of platelets was unaffected by inhibition of GPIbα but was reduced by GPVI deficiency, thus indicating that early platelet recruitment was independent of GPIbα and mediated by GPVI.
More precisely, GPVI initiated platelet adhesion by permitting platelet tethering but was not sufficient for subsequent stable adhesion, which required integrin αIIbβ3 activation. Platelets recruited to the inflamed glomerulus then stimulated neutrophil recruitment in an ADP and P-selectin-dependent way. 99, 110 Interestingly, whereas platelets enhanced neutrophil recruitment in this model, the opposite was also true. In fact, neutrophil depletion prior to glomerulonephritis induction markedly reduced How platelets recruited through GPVI at sites of neutrophil infiltration prevent bleeding independently of aggregation? Dampening of neutrophil histotoxic activities represents a mechanism of action by which platelets could limit injury and bleeding. This possibility has however been dismissed on the grounds that markers of neutrophil activation during IC-mediated inflammation were reduced in thrombocytopenic and GPVI −/− mice as compared to wild-type mice. 94 These data argued that platelets stimulated rather than prevent neutrophil activation during IC-mediated inflammation, and that GPVI contributed to this effect. They also added to growing indications that GPVI can regulate innate immune cell activation and function, 100, 123 an effect that might involve the interaction of GPVI with one of its newly identified ligand, EMMPRIN, a surface receptor widely expressed in human tumors but also platelets, monocytes, and activated lymphocytes. 101, 124 Considering that GPVI binds various components of the subendothelial matrix, it is plausible that single platelets or sheets of platelets stop bleeding by covering small areas where the basement membrane gets exposed and disrupted by neutrophils. The role of GPVI in this inflammation-associated hemostatic process might not be restricted to platelet adhesion as it was shown that defective ITAM signaling, either due to a genetic deficiency in SLP76 or to combined pharmacological inhibition of the Src-family kinases Syk and Bruton's tyrosine kinase (Btk) partially impaired the ability of platelets to prevent inflammatory bleeding. 94, 102 Thus, GPVImediated platelet responses likely also contribute to sealing of vascular breaches caused by neutrophils. In that regard, it was shown that even when not causing aggregation, collagen binding to GPVI can induce platelet shape change 125 and release of soluble platelet factors such as angiopoietin-1, serotonin, and ATP, all of which are regulators of endothelial cell barrier function or survival. 126 How platelet secretion and aggregation can be mechanistically uncoupled remains to be determined but a first glimpse was provided recently by studies showing the existence of specific forms and pathways of platelet secretion in response to low-dose agonists. 127, 128 A recent study by Deppermann et al., showed that mice lacking platelet alpha-and/or dense-granule secretion showed no signs of inflammatory bleeding in IC-induced dermatitis or LPS-induced lung inflammation. 113 These findings suggest that platelet shape change and spreading might be more important than granule secretion for GPVI-dependent inflammation-associated hemostasis.
| BACK TO THE PAST: DIRECT EVIDENCE THAT PLATELETS CAN SECURE INJURED VESSELS INDEPENDENTLY OF AGGREGATION
Recent data converge to suggest that non-aggregated platelets adhering, spreading and/or releasing their granular content, in part through GPVI engagement, help to seal neutrophil-induced vascular breaches, thereby providing hemostasis in inflamed tissues (Figure 1 ). 98 But is there any direct evidence of platelets maintaining vascular integrity in the absence of aggregation? In a series of studies ranging from the 1960s to the 1970s, using electron microscopy,
Hans Rudolf Baumgartner showed that platelets rapidly adhered and spread out to form a continuous monolayer that covered the subendothelium exposed following ballooning-induced endothelial denudation in large arteries (Figure 1 ). [129] [130] [131] In contrast to thrombi that disappeared rapidly, this "pseudo-endothelium" made of non- Areas of wider basement membrane exposure were covered by several platelets, however, "platelet aggregates as seen during the formation of platelet thrombi were never observed". 132 In studies contemporary to Baumgartner, Palade, Majno, Cotran, and other illustrious pathologists published electron microscopy images of the interactions between platelets and microvessels in the context of inflammation. 98 Most of these studies show images of single platelets sealing endothelial gaps in microvessels at sites of increased permeability or neutrophil extravasation (Figure 1 ). 98 Therefore, visual evidence that, besides fibrin deposits and platelet aggregates, nonaggregated platelets can repair small breaches in inflamed vessels has been available for over 50 years. Yet, it was only until recently that the importance of these interactions for the prevention of inflammatory bleeding, as well as their underlying mechanisms, including the role of GPVI engagement, were unraveled.
| GPVI SECURING INFLAMED VESSELS: CLINICAL IMPLICATIONS AND APPLICATIONS
In preclinical studies, GPVI antagonists have proven to effectively inhibit thrombosis without significantly affecting primary hemostasis. 42, 43 As a consequence, GPVI might appear as a new and ideal target for antithrombotic therapy that would combine efficacy with safety. In this context, the fact that GPVI deficiency or blockade in mice is associated with an increased risk of bleeding in the inflamed skin, 94, 102 heart, 103 and possibly lungs 102 ( Table 1 ), suggest that targeting GPVI might not be as safe as initially thought. Nevertheless, besides cutaneous petechiae which, as presented in the present review, can be caused by inflammation, inflammatory bleeding is not a common observation in GPVI-deficient patients. There are several possible explanations for the lack of clinical reports of inflammation-induced bleeding in GPVI-deficient patients. First, we know from mouse studies that the role of GPVI in inflammation-associated hemostasis can be partly compensated for through engagement of other platelet receptors like CLEC-2. 102, 122 Second, it is important to recall that platelets are extremely potent at preventing inflammatory bleeding, as inflammatory bleeding was observed only in mice with severe thrombocytopenia and could be rescued by restoring platelet counts to levels as low as 5-10% of normal mouse platelet count. 67, 68, 98 In a comparable manner, it was shown that even trace amounts of surface GPVI were sufficient to maintain residual function including adhesion to collagen under static conditions. 9, 135 Moreover, consistent with the notion that even a low copy number of functional GPVI is sufficient for hemostasis, the parents of the first GPVI-deficient patient identified as such had platelets who retained normal function despite containing approximately 50% the normal amount of GPVI. 3 Last but not least, the protective role of GPVI in inflammation observed in the inflamed skin and lungs cannot be generalized to all inflammatory situations. In fact, not all organs are prone to inflammatory bleeding 98 (Table 1) . No bleeding was observed in mice with severe thrombocytopenia that were subjected to rheumatoid arthritis or to peritonitis. 79, 80, 84, 94 Furthermore, even in organs that are prone to inflammatory bleeding, GPVI is not always required for inflammation-associated hemostasis (Table 1) . For example, GPVI was shown to be dispensable for the prevention of hemorrhagic
The early work of Hans R. Baumgartner showed that in case of minor injury restricted to the endothelial layer (e.g, endothelial denudation, vasodilatation, and opening of endothelial junctions), platelets adhere and spread over the exposed basement membrane acting as "bouche-trou", either individually or through the formation of a nonthrombogenic "pseudo-endothelium" in wider areas of denuded basement membrane. Notably, the adhesion of platelets to the exposed subendothelial matrix is collagenase-sensitive, indicating a possible role for platelet/collagen interactions, and thus for GPVI, in this function. Middle panel: Recent and early studies indicate that, in case of mild injury where the basement is damaged (e.g, by neutrophil infiltration during acute inflammatory reactions), platelets seal vascular breaches by filling endothelial gaps and/or bridging endothelial junctions over areas of basement membrane disruption. Platelet GPVI contributes to the recruitment and adhesion of platelets to these sites. Engagement of platelets through CLEC-2 by podoplanin-expressing cells in direct vicinity of blood vessels (e.g, fibroblasts and inflammatory macrophages) provides a backup mechanism in the absence of GPVI. Lower panel:
In a more classical view of hemostasis, in case of severe injury like in trauma or sustained inflammatory reactions, the exposure of the deeper layers of the vessel wall and/or of tissues surrounding vessels leads to thrombin generation and full platelet activation, thereby triggering platelet aggregation through integrin αIIbβ3
Minor injury (eg, basement membrane exposure)
Mild injury (eg, leukocyte transmigration) 
| CONCLUSION
Recent studies have shown that, in various inflammatory situations, and from the very onset of inflammation, platelets ensure hemostasis independently of aggregation. In some of these situations, exemplified by IC-mediated dermatitis, platelets recruited early to inflammation sites partly through GPVI seal small vascular breaches caused by infiltrating leukocytes, thereby preventing bleeding.
These recent data considered together with observations made in past electron microscopy studies indicate that sealing of those breaches involves platelets filling gaps in the endothelial lining and spreading over damaged areas of the exposed basement membrane.
Both GPVI adhesion and signaling properties would thus be required for this function. The role of GPVI in this unconventional form of hemostasis shows that platelets can stop bleeding in multiple ways, depending on the type and severity of vascular injury, which likely determine the pathways and extent of platelet activation in a context-dependent manner.
| ISTH BERLIN REPORT
The duality of platelets, which exert both potentially damaging and protective actions in inflamed tissues, 143 A series of studies converged to support the concept that platelets can ensure inflammation-associated hemostasis independently of major platelet activation pathways, but also that the functional hierarchy between platelet receptors for this function varies with the cause and site of inflammation. The group of Tom van der Poll showed that, in contrast to the previously reported role of GPVI and CLEC-2 in the prevention of bleeding in models of IC-induced dermatitis and LPS-induced lung injury, neither GPVI nor CLEC-2
were needed for inflammation-associated hemostasis in a model of sepsis induced by Klebsiella pneumoniae lung infection. 148, 149 Notably, GPVI-depleted mice showed increased bacterial growth in lungs, thus indicating that GPVI contributes to host defense during pneumonia-derived sepsis. In a model of inflammatory bowel disease induced by oral administration of dextran sodium sulfate, the group of Cécile Oury showed that prevention of intestinal bleeding by platelets involved P2X1 but not P2Y12 or GPVI. 150 In collaboration with the group of Steve Watson, we showed that GPVI played the major role in preventing bleeding in IC-mediated dermatitis, with CLEC-2 being involved only in the absence of GPVI. 62 In addition, we showed that neither receptor plays a prominent part in preventing bleeding in LPS-inflamed lungs, which partly relied on GPIb.
Collectively, these results demonstrate that the contribution of platelet adhesion receptors to vascular integrity varies between vascular beds and inflammatory challenges. Among the parameters that vary with the vascular bed and inflammatory stimulus, the type and expression levels of ligands of platelet activating and inhibitory receptors, the type of leukocytes involved, local hemodynamic factors (e.g, arterial vs. venous and systemic vs. pulmonary pressures and resistances), as well as the severity of the injury, likely contribute to determine how platelets are engaged for inflammation-associated hemostasis.
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